Knowledge HQ

This study combined PM21-particles with IL-12/15/18 (CAP) to expand NK cells. CAP-NK cells showed superior expansion in G-Rex 24, G-Rex 6M, and G-Rex 100M. The resulting cells exhibited memory-like properties, enhanced metabolic fitness, and improved in vivo persistence compared to PM21 alone.

This study describes Tmod cell therapy using a NOT gate to target widely expressed antigens like EGFR while sparing normal cells via an HLA-A*02 blocker. Primary T cells were transduced with CAR or Tmod lentivirus and cultured in G-Rex plates (G-Rex 10 for in vivo studies) to generate effector cells.

This study presents a GMP protocol for non-viral CAR-T production using piggyBac transposons. Expansion was performed in G-Rex 24 plates (low scale) and G-Rex 10/100 bottles (large scale) with irradiated allogeneic feeders. The feeder improved yield in lymphopenic patients without affecting VCN or phenotype.

This study describes AB248, a CD8 cis-targeted IL2 that selectively activates CD8+ T cells. B7H3 CAR-T cells were generated by stimulating T cells and transducing them in a 24-well G-Rex plate. The combination of CAR-T and CD8-targeted IL2 resulted in potent antitumor activity and complete tumor rejection in mice.

This study utilized the Tapestri platform to characterize CRISPR-Cas9 engineered CD8+ T cells targeting TRAC and TRBC loci. Activated T cells were nucleofected and cultured in 24-well G-Rex plates for 7 days. The analysis quantified on-target edits, off-target events, and translocations with single-cell granularity.

This study compares FBS and human platelet lysate (HPL) for expanding CAR-Vδ2 T cells. Cells expanded in G-Rex with HPL showed greater expansion and in vivo anti-tumor activity. HPL reduction of cellular senescence and apoptosis pathways contributed to improved persistence compared to FBS.

This study investigated incorporating TLR4 signaling domains into CD19 CARs to improve efficacy against solid tumors. Primary T cells were transduced with CAR lentiviral vectors and expanded for 7-10 days in G-Rex six-well plates. The modified CAR-Ts exhibited enhanced cytotoxicity and cytokine secretion.

This review explores non-viral genetic modification methods for NK cells to produce off-the-shelf CAR-NK therapies. It highlights manufacturing strategies, noting that K562mbIL12-41BBL feeder cells facilitate large-scale expansion of peripheral blood NK cells in gas-permeable static cell culture (G-REX).

This study details the development of a CD22-targeted nanobody-based CAR-T therapy. Primary human T cells were transduced with CD22sdCAR lentivirus and expanded in G-Rex 10M. The 1ug36-sdCAR candidate demonstrated significant in vivo therapeutic activity and favorable tissue specificity in xenograft models.

The study evaluates GPR65 as a target. TCR-T cells (NY-ESO1 or MAGE-A4) were produced in G-Rex 6 Well Plate systems.

This study engineers memory T cells to secrete IDUA for treating MPS I. Engineered Tm cells were cultured and expanded in 24-well G-Rex tissue culture plates.

The study investigates EphA3-targeted CAR T cells for glioblastoma. T cells were transduced and expanded in G-Rex 24 well plates.